Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trastuzumab Deruxtecan in Neoadjuvant HER2-positive Breast Cancer
NCT05900206Phase 2Recruiting
- Sponsor
- Karolinska University Hospital
- Start
- Oct 2023
- Primary completion
- Apr 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of trastuzumab deruxtecan in HER2-positive breast cancer, sponsored by Karolinska University Hospital. Started Oct 2023; status: recruiting.
02
Drugs
trastuzumab deruxtecan
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT05900206.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05900206.